Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - daratumumab???.1800mg/15ml - solucion inyectable - cada 15ml de solución contiene: daratumumab????????????????.1800mg

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - daratumumab 20 mg/ml - concentrado para solucion para perfusion - cada ml contiene: daratumumab 20 mg

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - una cápsula contiene: ibrutinib 140mg - capsula dura - una cápsula contiene: ibrutinib 140mg

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - cada ml contiene: palmitato de paliperidona 312 mg a: 312 mg de palmitato de paliperidona es equivalente a 200 mg de fracción activa de paliperidona. - suspension inyectable de liberacion prolongada - cada ml contiene: palmitato de paliperidona (a) 312 mg a: 312 mg de palmitato de paliperidona es equivalente a 200 mg de fracción activa de paliperidona.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - apalutamida 60mg - tableta recubierta de liberacion inmediata - cada tableta recubierta de liberación inmediata contiene 60mg de apalutamida (contenida en 240mg de 250mg/g de polvo secado por atomización (sdp) )

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag international nv belgica - cada ml contiene: palmitato de paliperidona (a) 312mg (a): 312 mg de palmitato de paliperidona es equivalente a 200 mg de fracción activa de paliperidona. - suspension inyectable de liberacion prolongada - cada ml contiene: palmitato de paliperidona (a) 312mg (a): 312 mg de palmitato de paliperidona es equivalente a 200 mg de fracción activa de paliperidona.

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen cilag international nv [be] belgium - palmitato de paliperidona 156.00 mg 156 mg de palmitato de paliperidona es equivalente a 100 mg de paliperidona fracción activa - suspension inyectable de liberacion prolongada - una jeringuilla precargada contiene: palmitato de paliperidona (a) 156.00 mg 156 mg de palmitato de paliperidona es equivalente a 100 mg de paliperidona fracción activa

Ecuador - español - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

janssen-cilag interntional nv [be] belgium - cada tableta recubierta contiene: macitentan 10 mg - tableta recubierta - cada tableta recubierta contiene: macitentan 10 mg

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - paliperidona - schizophrenia; psychotic disorders - psicolépticos - invega está indicado para el tratamiento de la esquizofrenia en adultos y en adolescentes de 15 años en adelante. comercial invega está indicado para el tratamiento del trastorno esquizoafectivo en adultos.

Unión Europea - español - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecciones por vih - antivirales para uso sistémico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.